Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (NASDAQ: PODD) is a Massachusetts-based medical device company known for its Omnipod tubeless insulin pump platform, which is designed to simplify life for people with diabetes. The Insulet news feed on Stock Titan aggregates company announcements, earnings updates, product milestones, and strategic disclosures that shape the PODD stock narrative and the evolution of automated insulin delivery.
Investors and observers can follow news on the Omnipod Insulin Management System and the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors to automate insulin dosing without multiple daily injections or fingersticks. Company releases highlight regulatory clearances, such as FDA 510(k) decisions for Omnipod 5 algorithm enhancements, as well as technology demonstrations at events like the Consumer Electronics Show, where Insulet presents its vision for “liveable technology” in connected health.
The PODD news stream also covers quarterly and annual financial results, long-range financial outlooks, and Investor Day presentations in which Insulet outlines its growth strategy in automated insulin delivery markets. Additional updates include sustainability initiatives like the expansion of the U.S. Pod recycling program, collaborations such as the Omnipod Mango color partnership with Pantone, and governance developments including executive and board appointments.
By reviewing Insulet news on this page, readers can track how the company’s Omnipod platform, innovation roadmap, financial performance, and corporate actions intersect. Bookmark this feed to monitor new product features, regulatory developments, strategic events, and other disclosures that may be relevant to understanding PODD as both a medical technology business and a publicly traded stock.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced its participation in the William Blair & Company 42nd Annual Growth Stock Conference in Chicago on June 8, 2022, at 9:00 a.m. (Eastern Time). The presentation will be available for live audio webcast and a replay will follow. Insulet's Omnipod product platform aims to simplify diabetes management with innovative solutions, including the Omnipod 5 Automated Insulin Delivery System. This system is integrated with a continuous glucose monitor, providing a seamless insulin delivery experience.
Insulet Corporation (NASDAQ: PODD) has announced the groundbreaking of a new manufacturing facility in Johor Bahru, Malaysia, aimed at enhancing its global manufacturing capacity. The facility will occupy around 400,000 square feet and is projected to cost $200 million over five years, creating over 500 full-time jobs upon full operation. The new site will produce the Omnipod Insulin Management System and implement environmentally responsible practices, seeking LEED certification. Production is expected to commence by mid-2024.
Bigfoot Biomedical has appointed Matt Rainville as Chief Commercial Officer, aiming to enhance the Bigfoot Unity® Diabetes Management Program. With over 20 years in healthcare commercialization, including roles at Insulet and Eli Lilly, Rainville will focus on expanding access to diabetes management solutions. CEO Jeffrey Brewer emphasized that this hiring is crucial as they seek to grow their presence in the market for insulin management. Rainville's leadership is expected to drive adoption of their innovative solutions for diabetes care.
Insulet Corporation announces leadership changes with Jim Hollingshead succeeding Shacey Petrovic as President and CEO, effective June 1, 2022. Petrovic steps down for personal family reasons but will remain on the Board and serve as an advisor until May 2023. Under Petrovic's leadership since January 2019, Insulet achieved revenue exceeding $1 billion in 2021, reflecting consistent growth. The company anticipates revenue growth of 12% to 16% for 2022, driven by its Omnipod product line, despite facing macroeconomic and inflationary pressures.
Insulet Corporation (NASDAQ: PODD) reported a strong financial performance for Q1 2022, with revenue of $295.4 million, a 17.1% increase year-over-year. Total Omnipod revenue rose 15.6% to $269.5 million. Operating income improved to $37.9 million, a significant rise from $16.3 million last year. The company also achieved a gross margin of 71.0%. For 2022, Insulet reaffirms revenue growth guidance of 12% to 16%, while addressing inflationary pressures affecting operating margins.
Summary not available.
Insulet Corporation (NASDAQ: PODD) presented studies on its Omnipod 5 Automated Insulin Delivery System for type 2 diabetes at the ATTD conference in Barcelona. Results showed a significant average HbA1c reduction of 1.3% and a 31.4% decrease in insulin use among participants. User satisfaction was high, with a System Usability Scale score of 90.5. Additionally, data on type 1 diabetes outcomes were shared, with five presentations scheduled. Insulet aims to broaden access to the Omnipod 5, currently cleared for type 1 diabetes management in the U.S.
Insulet Corporation (NASDAQ: PODD) announces its financial results for Q1 2022 will be released on May 5, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Insulet, a leader in tubeless insulin pump technology, provides innovative solutions for diabetes management through its Omnipod products. The Company aims to simplify insulin delivery with its unique and wearable Pod design, which operates for up to three days. The latest product is the Omnipod® 5, an automated system integrated with continuous glucose monitoring.
Insulet Corporation (NASDAQ: PODD) reported financial results for 2021, achieving over $1 billion in annual revenue for the first time, reflecting a 21.5% increase from the prior year. The Omnipod product line generated $1.0 billion in revenue, with U.S. sales rising 23.6%. The company recorded an operating income of $126 million and a net income of $16.8 million. The recent clearance of the Omnipod 5 automated insulin delivery system by the U.S. FDA is a notable achievement. For 2022, Insulet expects revenue growth between 12% to 16% and a 100 basis point increase in operating margins.
Insulet Corporation (NASDAQ: PODD) launches a unique initiative integrating diabetes representation into the video game Animal Crossing: New Horizons. Players can download designs for insulin pump outfits and access Omnipod Bay, a themed island promoting diabetes awareness through playful activities. A recent survey revealed that 94% of people with type 1 diabetes value cultural representation, yet 51% feel underrepresented. The launch event takes place today at 3:00 PM ET, featuring content creators raising funds for JDRF, with Insulet matching donations.